[{"orgOrder":0,"company":"NX Development Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NX Development Corp \/ Undisclosed"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"NX Development Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ NX Development Corp","highestDevelopmentStatusID":"6","companyTruncated":"NX Development Corp \/ NX Development Corp"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"NX Development Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NX Development Corp \/ NX Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"NX Development Corp \/ NX Development Corp"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NX Development Corp \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by NX Development Corp

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Sarcoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 26, 2025

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : University of Colorado, Denver

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Gleolan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 07, 2023

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 01, 2021

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Icahn School of Medicine at Mount Sinai

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Meningioma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2020

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank